Patrizia Froesch

Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry

Oliver Gautschi, Julie Milia, Thomas Filleron et al. · Journal of Clinical Oncology · 2017 · 349 citations · Full text

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet et al. · Journal of Clinical Oncology · 2021 · 336 citations

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Rafael Rosell, Urania Dafni, Enriqueta Felip et al. · The Lancet Respiratory Medicine · 2017 · 182 citations

Medicine, Pathology, Immune Checkpoint Inhibitor +6

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma

Yannis Metaxas, Gareth Rivalland, Laetitia Mauti et al. · Journal of Thoracic Oncology · 2018 · 91 citations · Full text

Malignant Disease, Radiation Oncology, Palliative Immunotherapy +1

Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

Sabine Schmid, Oliver Gautschi, Sacha I. Rothschild et al. · Journal of Thoracic Oncology · 2016 · 72 citations · Full text

De Novo Egfr, Medicine, Pathology +6